drugset
Drugs / MVA-SARS-2-ST
last change Nov 2023 re-read 3 minutes ago

MVA-SARS-2-ST

Vaccine

Developed for
COVID-19
Investigated by
German Center for Infection Research · IDT Biologika · University Medical Center Hamburg-Eppendorf · Clinical Trial Center North (CTC North GmbH & Co. KG) · Hannover Medical School · Ludwig-Maximilians - University of Munich
+1 more · Philipps University Marburg

Trials 2

today NCT05226390 · Ph 1 NCT04895449 · Ph 1
20222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT05226390 Feb 2022 → Nov 2023 — Hannover Medical School Terminated No outcome recorded Stop: Enrollment
Phase 1 NCT04895449 Jul 2021 → Nov 2022 COVID-19 University Medical Center Hamburg-Eppendorf Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as MVA-SARS-2-ST ClinicalTrials.gov intervention name — accepted as the source's own label NCT04895449 ↗
1

NCT05226390 ↗
Modality Vaccine “The vaccine contains a Modified Vaccinia Virus Ankara (MVA) vector expressing a stabilized SARS-CoV-2 spike protein (S).” NCT04895449 ↗
Route Intramuscular “i.m. vaccine administration” NCT04895449 ↗